|MDACC Study No:||2013-0062(2009-0493GYN) (clinicaltrials.gov NCT No: NCT01091428)|
|Title:||Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer|
|Principal Investigator:||Robert Coleman|
|Treatment Agent:||MLN8237; Paclitaxel|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
MLN8237 (alisertib) and paclitaxel can help to control advanced ovarian,
fallopian tube, or peritoneal cancer. Researchers will compare the effects of
this combination to those of paclitaxel alone. The safety of the study drug
combination will also be studied.
MLN8237 is designed to block certain proteins that cause cancer cells to grow
and divide. This blocking may cause the cancer cells to die.
Paclitaxel is designed to block cancer cells from dividing, which may cause
them to die.